4.6 Article

Trends in Corneal Transplantation from 2001 to 2016 in Germany: A Report of the DOG-Section Cornea and its Keratoplasty Registry

Journal

AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume 188, Issue -, Pages 91-98

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2018.01.018

Keywords

-

Categories

Funding

  1. German Research Council of the German Research Foundation (Deutsche Forschungsgemeinschaft DFG, Bonn, Germany)
  2. Santen GmbH (Munich, Germany)
  3. Ursapharm GmbH (Saarbrucken, Germany)
  4. Alcon Pharma GmbH (Freiburg, Germany)
  5. Bayer AG (Leverkusen, Germany)
  6. TearLab Inc (San Diego, California, USA)
  7. TearScience (Morrisville, North Carolina, USA)
  8. Allergan GmbH (Frankfurt, Germany)
  9. Bausch & Lomb Inc. (Rochester, New York, USA)
  10. Chiesi GmbH (Hamburg, Germany)
  11. Dompe (Milano, Italy)
  12. Oculus Pharma Ltd (Kanpur, India)
  13. Shire Pharmaceuticals (Dublin, Ireland)
  14. TearLab Inc
  15. TearScience
  16. Thea Pharma GmbH (Berlin, Germany)
  17. VISUfarma B.V. (Amsterdam, The Netherlands)

Ask authors/readers for more resources

PURPOSE: The purpose of this retrospective panel study was to provide an overview of absolute numbers and of trends in the types of and indications for corneal transplantation in Germany from 2001 to 2016. METHODS: A questionnaire about absolute numbers, types of transplantation, and indications was sent to 111 ophthalmologic departments in Germany, out of which 94 (85%) provided their data. RESULTS: Since the year 2001, the number of corneal transplantations has increased by 1.5-fold, from 4730 penetrating keratoplasties (PICPs) in 2001 to 7325 penetrating and lamellar keratoplasties in 2016. The shift from penetrating to lamellar procedures began in 2006. In 2014, lamellar procedures (231 [4%] anterior and 2883 [49%] posterior lamellar keratoplasties) surpassed PKPs (2721, 47%) for the first time. Main indications for keratoplasty in Germany (2016) are Fuchs endothelial corneal dystrophy (46%), pseudophakic corneal decompensation (bullous keratopathy, 13%), repeated keratoplasty after graft failure (11%), keratoconus (8%), and corneal scarring (6%; others: 16%). The number of Descemet membrane endothelial keratoplasties (DMEKs) was 12 times higher (3850, 53%) than Descemet stripping automated endothelial keratoplasties (DSAEKs, 319, 4.4%) in 2016. The proportion of deep anterior lamellar keratoplasties (DALKs) never exceeded 6% (269 in 2011). CONCLUSIONS: The number of keratoplasties in Germany has increased from 2001 to 2016. Since 2014, posterior lamellar keratoplasties have surpassed PKPs. There was a constant increase of DMEKs, with a 12-fold higher number compared to DSAEKs in 2016. The shorter recovery time after DMEK seems to contribute to the trend toward earlier operative intervention in corneal endothelial diseases. (C) 2018 The Author (s). Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available